Martin A. Ohrt
CEO
LIITA Care ApS
Copenhagen, Denmark
3 profile visits
70% of deployed soldiers get respiratory infections—grounding more troops than combat injuries. Can we talk resilience without addressing respiratory health?
My organisation
LIITA Care develops clinically grounded, field-ready solutions to reduce respiratory tract infections (RTIs), strengthen soldier resilience, and mitigate antimicrobial resistance (AMR) in military environments.
Our lead innovation, Breathox®, is a dry powder sodium chloride inhaler designed for early, non-pharmaceutical intervention against viral RTIs. Portable, rugged, and drug-free, it supports operational readiness by preventing minor infections from escalating into mission-disrupting conditions. Breathox® is currently in use in both civilian and military settings, with real-world evidence emerging from deployment zones (Ukraine).
As modern defence strategies increasingly recognise resilience as a core readiness capability, LIITA Care contributes by protecting one of the most vulnerable and under-prioritised systems in the field: the respiratory tract.